Skip to main content
Top
Published in: Endocrine Pathology 4/2017

01-12-2017

Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas

Authors: Julieann C. Lee, Melike Pekmezci, Jonathan L. Lavezo, Hannes Vogel, Laurence Katznelson, Merav Fraenkel, Griffith Harsh, Mohanpal Dulai, Arie Perry, Tarik Tihan

Published in: Endocrine Pathology | Issue 4/2017

Login to get access

Abstract

Pit-1 immunostaining is not routinely used in the characterization of pituitary adenomas, and its utility in distinguishing adenomas dedicated towards the lactotroph, somatotroph, and thyrotroph lineage from null cell adenomas warrants further evaluation. Pituitary adenomas that were negative for expression of a basic panel of hormonal markers (ACTH, prolactin, and growth hormone) were further evaluated for TSH, SF-1, and Pit-1 expression using a tissue microarray. Among the 147 identified pituitary adenomas that were negative for ACTH, prolactin, growth hormone, and TSH, expression of SF-1 was present in 68 cases (46%). Of the remaining 72 cases with sufficient tissue for further analysis, four were Pit-1 positive (6% of the adenomas negative for ACTH, prolactin, growth hormone, TSH, and SF-1); the remaining 68 were potentially null cell adenomas. Two of the Pit-1-positive adenomas displayed a paranuclear CAM 5.2 staining pattern suggestive of a sparsely granulated somatotroph adenoma; however, only one case contained fibrous bodies within a majority of the adenoma cells. Our data suggests that Pit-1 can be utilized as a second tier immunostain in cases of clinically non-functioning adenomas that are immunonegative for ACTH, prolactin, growth hormone, TSH, and SF-1 in order to further segregate rare cases of Pit-1-positive adenomas from null cell adenomas. Pit-1 immunostaining can recognize rare cases of sparsely granulated somatotroph adenomas that appear immunonegative for growth hormone, as well as rare cases of other Pit-1-positive adenomas that are negative for Pit-1 lineage hormones. Overall, pituitary adenomas of the Pit-1 lineage that do not produce prolactin, growth hormone, or TSH are rare, with only four cases identified in the current study.
Literature
1.
go back to reference Asa SL and Ezzat S (2009) The pathogenesis of pituitary tumors. Annual Review of Pathology 4:97–126.CrossRefPubMed Asa SL and Ezzat S (2009) The pathogenesis of pituitary tumors. Annual Review of Pathology 4:97–126.CrossRefPubMed
2.
go back to reference Asa SL (2011) AFIP Atlas of Tumor Pathology: Tumors of the Pituitary Gland. Asa SL (2011) AFIP Atlas of Tumor Pathology: Tumors of the Pituitary Gland.
3.
go back to reference Asa SL et al., (1993) Cell type-specific expression of the pituitary transcription activator Pit-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab;77(5):1275–1280.PubMed Asa SL et al., (1993) Cell type-specific expression of the pituitary transcription activator Pit-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab;77(5):1275–1280.PubMed
4.
go back to reference Balogun JA et al., (2015) Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavorial Characteristics. Endocrine Pathology 26:63–70.CrossRefPubMed Balogun JA et al., (2015) Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavorial Characteristics. Endocrine Pathology 26:63–70.CrossRefPubMed
5.
go back to reference Nishioka, H et al., (2015) The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocrine Pathology 26:349–355.CrossRefPubMed Nishioka, H et al., (2015) The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocrine Pathology 26:349–355.CrossRefPubMed
6.
go back to reference Sjostedt E et al., (2017) A specific antibody to detect transcription factor T-pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol 134:675–677.CrossRef Sjostedt E et al., (2017) A specific antibody to detect transcription factor T-pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol 134:675–677.CrossRef
7.
go back to reference Jahangiri A et al., (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73:8–17.CrossRefPubMed Jahangiri A et al., (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73:8–17.CrossRefPubMed
8.
go back to reference Syro LV et al., (2017) Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary 20:84–92.CrossRefPubMed Syro LV et al., (2017) Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary 20:84–92.CrossRefPubMed
9.
go back to reference Yamada S et al., (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33:20–27.PubMed Yamada S et al., (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33:20–27.PubMed
10.
go back to reference Cheng-Chia L et al., (2015) Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18:326–334.CrossRef Cheng-Chia L et al., (2015) Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18:326–334.CrossRef
11.
go back to reference McDonald WC et al., (2017) Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A rational starting place for the immunohistochemical characterization of pituitary adenoma. Archives of pathology and laboratory medicine 141:104–112.CrossRefPubMed McDonald WC et al., (2017) Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A rational starting place for the immunohistochemical characterization of pituitary adenoma. Archives of pathology and laboratory medicine 141:104–112.CrossRefPubMed
12.
go back to reference Yamada S et al., (1996) Pit-1 gene expression in human pituitary adenomas using reverse transcription polymerase chain reaction method. Clin Endocrinol 45:263–272.CrossRef Yamada S et al., (1996) Pit-1 gene expression in human pituitary adenomas using reverse transcription polymerase chain reaction method. Clin Endocrinol 45:263–272.CrossRef
13.
go back to reference Mayr B et al., (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. European Journal of Endocrinology 169:391–400.CrossRefPubMed Mayr B et al., (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. European Journal of Endocrinology 169:391–400.CrossRefPubMed
Metadata
Title
Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas
Authors
Julieann C. Lee
Melike Pekmezci
Jonathan L. Lavezo
Hannes Vogel
Laurence Katznelson
Merav Fraenkel
Griffith Harsh
Mohanpal Dulai
Arie Perry
Tarik Tihan
Publication date
01-12-2017
Publisher
Springer US
Published in
Endocrine Pathology / Issue 4/2017
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-017-9503-6

Other articles of this Issue 4/2017

Endocrine Pathology 4/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.